TegoScience Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
TegoScience's earnings have been declining at an average annual rate of -7.9%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 1.5% per year. TegoScience's return on equity is 6.6%, and it has net margins of 48.1%.
Anahtar bilgiler
-7.9%
Kazanç büyüme oranı
-8.0%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 11.7% |
| Gelir büyüme oranı | 1.5% |
| Özkaynak getirisi | 6.6% |
| Net Marj | 48.1% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Gelir ve Gider Dağılımı
TegoScience nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 6,974 | 3,352 | 3,613 | 2,474 |
| 31 Mar 24 | 7,194 | -2,659 | 3,475 | 2,593 |
| 31 Dec 23 | 7,772 | -2,323 | 3,656 | 2,576 |
| 30 Sep 23 | 8,016 | -1,404 | 2,716 | 2,971 |
| 30 Jun 23 | 8,134 | -1,301 | 2,870 | 2,971 |
| 31 Mar 23 | 8,202 | 235 | 3,729 | 2,027 |
| 31 Dec 22 | 7,678 | 265 | 3,534 | 1,608 |
| 30 Sep 22 | 8,426 | 1,349 | 4,854 | 412 |
| 30 Jun 22 | 8,341 | 1,254 | 4,014 | 1,044 |
| 31 Mar 22 | 8,162 | 432 | 3,562 | 2,062 |
| 31 Dec 21 | 8,300 | 139 | 3,906 | 2,328 |
| 30 Sep 21 | 7,573 | -479 | 4,142 | 2,421 |
| 30 Jun 21 | 8,235 | 71 | 4,089 | 2,284 |
| 31 Mar 21 | 8,455 | 993 | 3,588 | 1,992 |
| 31 Dec 20 | 8,789 | 1,831 | 3,002 | 1,852 |
| 30 Sep 20 | 8,323 | 1,761 | 2,671 | 1,759 |
| 30 Jun 20 | 7,580 | 1,338 | 2,543 | 1,803 |
| 31 Mar 20 | 6,983 | 1,273 | 2,437 | 1,732 |
| 31 Dec 19 | 6,346 | 856 | 2,409 | 1,700 |
| 30 Sep 19 | 6,723 | -2,058 | 2,612 | 1,720 |
| 30 Jun 19 | 6,849 | -2,142 | 2,763 | 1,659 |
| 31 Mar 19 | 7,366 | -776 | 2,939 | 1,762 |
| 31 Dec 18 | 7,850 | -1,826 | 3,164 | 1,743 |
| 30 Sep 18 | 8,042 | -3,071 | 3,226 | 1,762 |
| 30 Jun 18 | 8,245 | -2,888 | 3,350 | 1,545 |
| 31 Mar 18 | 8,331 | -7,515 | 3,413 | 1,583 |
| 31 Dec 17 | 8,642 | -6,021 | 3,348 | 1,568 |
| 30 Sep 17 | 8,568 | -2,985 | 3,182 | 1,376 |
| 30 Jun 17 | 8,568 | -2,610 | 3,000 | 1,433 |
| 31 Mar 17 | 8,549 | 776 | 2,879 | 1,415 |
| 31 Dec 16 | 8,343 | 772 | 2,857 | 1,433 |
| 30 Sep 16 | 8,049 | 1,842 | 2,907 | 1,583 |
| 30 Jun 16 | 7,981 | 1,841 | 2,845 | 1,678 |
| 31 Dec 15 | 7,492 | 1,473 | 2,925 | 1,605 |
Kaliteli Kazançlar: A191420 has a large one-off gain of ₩3.7B impacting its last 12 months of financial results to 30th June, 2024.
Büyüyen Kar Marjı: A191420 became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: A191420 has become profitable over the past 5 years, growing earnings by -7.9% per year.
Büyüme Hızlandırma: A191420 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: A191420 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Özkaynak Getirisi
Yüksek ROE: A191420's Return on Equity (6.6%) is considered low.